Daeryun Law Firm holds a webinar on ‘2025 Pharmaceutical and Bio Settlement’ on the 28th

Analysis of precedents and inspection of the latest regulatory environment, including the Digital Medical Products Act
Pharmaceutical and bio industries influenced by a single ruling
Sharing solutions that can be applied to business

An opportunity will be provided to conduct an in-depth analysis of the patent disputes and personnel and labor issues that heated up the pharmaceutical and bio industries last year and to explore corporate response strategies to the changing regulatory environment.

Daeryun Law Firm announced on the 15th that it will hold a webinar (online seminar) '2025 Pharmaceutical and Bio Sector Settlement - Medical, Bio and Healthcare Group Seminar' on the 28th.

The lecturer will be attorney Lee Il-hyung, head of Daeryun Pharmaceutical Bio Healthcare Center. This lawyer, who holds a pharmacist's license, is an expert with extensive litigation experience, ranging from pharmaceutical patent disputes to healthcare regulatory response and legal advice.

The webinar largely consists of analyzing precedents and examining major laws and regulations in the pharmaceutical and bio fields of last year. In particular, attorney Lee Il-hyung personally carries out cases and delivers practical implications focusing on major precedents in which legal principles were argued.

First, through the '13-valent pneumococcal vaccine ruling', we look in detail at the latest issues in the patent field, such as ▲whether the production of semi-finished products constitutes patent infringement (direct infringement) ▲the principle of territoriality and the meaning of domestic production ▲the scope of application of exceptions to experimental implementation (research purposes) under the Patent Act.

Next, we analyze rulings related to illegal dispatch, a chronic risk in the pharmaceutical industry, from a human resources and labor perspective. The key issue is whether compliance with the main contractor's standard operating instructions (SOP) can be viewed as actual command and order. Attorney Lee plans to explain the criteria for judging illegal dispatch based on relevant precedents and present specific risk management measures for the operation of subcontractors in the pharmaceutical and bio industry.

Lastly, we plan to examine changes in major laws and regulations, such as the 'Digital Medical Products Act' that has been in effect since last year, and share compliance points that companies should not miss and practical countermeasures.

Daeryun Kim Kook-il, CEO of Management, said, "Patents, regulations, and employment structures are intertwined in the biopharmaceutical industry, so even a single ruling can have a significant impact on corporate management. Through this webinar, it will be an opportunity to obtain practical risk management solutions that can be immediately applied to the field based on the perspective of lawyer Lee, who has personally handled related cases."

This webinar will be held online, and you can apply for participation on Daeryun Law Firm’s official website. Applicants will be separately notified of the access link.

[View full article]
Medipana - Daeryun Law Firm holds a webinar on '2025 Pharmaceutical and Bio Settlement' on the 28th (Go here)
International Newspaper - Daeryun holds ‘2025 Pharmaceutical/Bio Settlement’ webinar… “Summary of key precedents” (Shortcut)